Guidance

UK NSC disease, clinical effectiveness and cost effectiveness modelling

This document outlines the UK National Screening Committee’s systematic approach to the use of decision analytic modelling as part of the evidence review process

• From: UK National Screening Committee
• Published: 29 September 2022

Documents

UK NSC disease, clinical effectiveness and cost effectiveness modelling

HTML

Details

This document supports the following recommendation made by the 4 UK chief medical officers (CMOs) for the expanded remit of the UK National Screening Committee (UK NSC) following the independent review of adult screening programmes in England:

It is suggested that the secretariat for the new UK NSC expands the evidence review process to include potential targeted screening programmes and should consider as a minimum:

• any additional steps that need to be factored in for proposals for targeted screening programmes
• the process for working with the National institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) on clinical care guidelines
• any additional steps for evaluating a stratified screening approach for either population or targeted screening programmes

Email uknsc@dhsc.gov.uk if you have any queries about this publication, making sure you include its full title.

Published 29 September 2022